ARVN

Arvinas, Inc. (ARVN) is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, pioneering the development of novel therapeutics through its proprietary PROTAC® technology aimed at selectively degrading disease-causing proteins. Focused primarily on oncology and other serious disorders, the company is strategically positioned to address significant unmet medical needs with its robust pipeline of product candidates. By advancing innovative protein modulation techniques, Arvinas is poised to potentially revolutionize treatment approaches in the biopharmaceutical sector, enhancing patient outcomes and capitalizing on the growing interest in targeted therapies.